Viewing Study NCT04893551


Ignite Creation Date: 2025-12-24 @ 11:39 PM
Ignite Modification Date: 2026-01-01 @ 1:45 AM
Study NCT ID: NCT04893551
Status: TERMINATED
Last Update Posted: 2023-04-20
First Post: 2021-05-17
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants
Sponsor: BerGenBio ASA
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module